CYP3A4 and prostate cancer: In addition, the CYP3A4 participates in the process of metabolism and the development of resistance (Ikezoe et al., 2004; Van Eijk et al., 2019), while indinavir as a potent inhibitor of CYP3A4 is thought to enhance the therapeutic effects of anticancer drugs in androgen-independent prostate cancer cells.